67 related articles for article (PubMed ID: 22822591)
1. Abiraterone. After prostate cancer treatment failure: 4-month survival advantage.
Prescrire Int; 2012 Jun; 21(128):147-9. PubMed ID: 22822591
[TBL] [Abstract][Full Text] [Related]
2. Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer.
Chi KN; Tolcher A; Lee P; Rosen PJ; Kollmannsberger CK; Papadopoulos KP; Patnaik A; Molina A; Jiao J; Pankras C; Kaiser B; Bernard A; Tran N; Acharya M
Cancer Chemother Pharmacol; 2013 Jan; 71(1):237-44. PubMed ID: 23064959
[TBL] [Abstract][Full Text] [Related]
3. [Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
Turitto G; Di Bisceglie M; Moraca L; Sasso N; Sepede C; Suriano A; Romito S
Recenti Prog Med; 2012 Feb; 103(2):74-8. PubMed ID: 22430753
[TBL] [Abstract][Full Text] [Related]
4. The role of abiraterone in the management of metastatic castration-resistant prostate cancer.
Rawlinson A; Mohammed A; Beatty J; Bell R; Miller M
Expert Rev Anticancer Ther; 2012 Apr; 12(4):429-37. PubMed ID: 22500680
[TBL] [Abstract][Full Text] [Related]
5. Abiraterone for the treatment of metastatic castrate-resistant prostate cancer.
Beckett RD; Rodeffer KM; Snodgrass R
Ann Pharmacother; 2012; 46(7-8):1016-24. PubMed ID: 22714819
[TBL] [Abstract][Full Text] [Related]
6. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy.
Harland S; Staffurth J; Molina A; Hao Y; Gagnon DD; Sternberg CN; Cella D; Fizazi K; Logothetis CJ; Kheoh T; Haqq CM; de Bono JS; Scher HI;
Eur J Cancer; 2013 Nov; 49(17):3648-57. PubMed ID: 23973186
[TBL] [Abstract][Full Text] [Related]
7. Abiraterone and metastatic prostate cancer: delays pain onset, cytotoxic therapy, and possibly death.
Prescrire Int; 2014 Feb; 23(146):40-1. PubMed ID: 24669383
[TBL] [Abstract][Full Text] [Related]
8. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
Borden LS; Clark PE; Lovato J; Hall MC; Stindt D; Harmon M; M Mohler R; Torti FM
Cancer; 2006 Sep; 107(5):1093-100. PubMed ID: 16888761
[TBL] [Abstract][Full Text] [Related]
9. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
Sternberg CN; Petrylak DP; Sartor O; Witjes JA; Demkow T; Ferrero JM; Eymard JC; Falcon S; CalabrĂ² F; James N; Bodrogi I; Harper P; Wirth M; Berry W; Petrone ME; McKearn TJ; Noursalehi M; George M; Rozencweig M
J Clin Oncol; 2009 Nov; 27(32):5431-8. PubMed ID: 19805692
[TBL] [Abstract][Full Text] [Related]
10. Clinical roundtable monograph: new and emerging treatments for advanced prostate cancer.
George DJ; Kantoff PW; Lin DW
Clin Adv Hematol Oncol; 2011 Jun; 9(6):1-11; discussion 11-5. PubMed ID: 21941983
[TBL] [Abstract][Full Text] [Related]
11. Doxetaxel: new indication. Prostate cancer: a few more weeks.
Prescrire Int; 2006 Feb; 15(81):6-7. PubMed ID: 16548096
[TBL] [Abstract][Full Text] [Related]
12. Abiraterone and increased survival in metastatic prostate cancer.
Berruti A; Pia A; Terzolo M
N Engl J Med; 2011 Aug; 365(8):766; author reply 767-8. PubMed ID: 21864182
[No Abstract] [Full Text] [Related]
13. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.
Morris MJ; Kelly WK; Slovin S; Ryan C; Eicher C; Heller G; Scher HI
J Urol; 2007 Dec; 178(6):2378-83; discussion 2383-4. PubMed ID: 17936848
[TBL] [Abstract][Full Text] [Related]
15. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
Pummer K; Lehnert M; Stettner H; Hubmer G
Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
[TBL] [Abstract][Full Text] [Related]
17. Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer.
Tagawa ST; Beltran H
Asian J Androl; 2011 Nov; 13(6):785-6. PubMed ID: 21857690
[No Abstract] [Full Text] [Related]
18. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
19. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
Ernst DS; Tannock IF; Winquist EW; Venner PM; Reyno L; Moore MJ; Chi K; Ding K; Elliott C; Parulekar W
J Clin Oncol; 2003 Sep; 21(17):3335-42. PubMed ID: 12947070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]